-
2024-515344-23-00
4
2021-06-17
local advenced pancreatic adenocarcinoma
-
2024-517215-67-00
5
2021-06-11
Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elder
-
2024-516181-11-00
4
2021-06-10
RELAPSE/REFRACTORY B-CELL LYMPHOMA.
-
2024-514025-30-00
4
2021-03-25
Ocular conservative treatment for retinoblastoma
-
2024-516623-14-00
4
2021-03-17
EBV+ primary imunodeficiency lymphoproliferative disease (LPD)
-
2024-515384-62-00
5
2020-10-09
Soft Tissue Sarcoma
-
2023-508432-53-00
4
2020-09-22
Systemic sclerosis
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2024-517841-16-00
6
2020-07-09
Neurogenic Orthostatic Hypotension
-
2024-515276-12-00
5
2020-07-01
Postpartum Hemorrhage
-
2023-506914-32-00
4
2020-05-05
Pan tumor
-
2024-514637-37-00
5
2020-02-11
Patients with bone sarcomas other than chordoma, who have no residual
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-507256-76-00
6
2020-01-14
Ulcerative colitis
-
2024-510580-28-00
5
2019-06-05
Middle or low locally advanced resectable rectal carcinoma
-
2024-515690-10-00
9
2019-05-10
Follicular B-cell non-Hodgkin's lymphoma
-
2024-512034-14-00
5
2019-03-04
severe trauma
-
2024-512002-26-00
4
2019-02-19
Muscle-invasive bladder cancer
-
2024-512629-97-00
4
2019-01-23
Patients with locally advanced or metastatic low grade endometrial str
-
2024-514094-22-00
5
2019-01-18
Intrecerebral Haemorrhage
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2024-514780-26-00
4
2018-10-23
Patients ≤50 years old with high-risk osteosarcoma (defined as metasta
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-513627-16-01
7
2018-03-28
Colorectal cancer metastatic